LIVE
VRTX
Vertex Pharmaceuticals Incorporated · Healthcare
$451.63
+3.99% this month
VERSUS
⟷
COMPARE
REGN
Regeneron Pharmaceuticals, Inc. · Healthcare
$609.94
-3.23% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
VRTX
2
REGN
3
Comparison scoreboard
REGN LEADS 3/5AI Score
VRTX ✓50.5
REGN 42.1
1Y Return
VRTX +2.18%
REGN ✓+19.86%
Fwd P/E
VRTX 20.72
REGN ✓11.38
Target Up.
VRTX +23.32%
REGN ✓+36.13%
Op. Margin
VRTX ✓38.13%
REGN 20.66%
Metrics last refreshed: 6/20/2026
Quick take
VRTX vs REGN Stock Comparison: AI Score, Valuation, Performance and Upside
Vertex and Regeneron are two of the highest-quality mid/large-cap biotech franchises — Vertex with its CF near-monopoly, and Regeneron with Dupixent's multi-indication immunology leadership. Both generate substantial free cash flow from their lead franchises and are investing in pipeline diversification. Vertex has the more concentrated franchise risk (CF) but is diversifying into large new markets; Regeneron has a broader platform with Dupixent still in high-growth expansion.
VRTX vs REGN is a comparison between the rare disease near-monopolist expanding into new large categories (Vertex) and the antibody biology platform company with a multi-indication blockbuster (Regeneron) — both are premium biotech holdings but with different growth trajectories and pipeline risk profiles.
Live analysis · updated 6/20/2026
REGN holds the edge across 3 of 5 key metrics in this comparison. REGN leads on both 1-year return (+19.86%) and forward P/E (11.38x vs 20.72x for VRTX), a relatively favorable combination of momentum and valuation. On fundamentals, REGN is growing revenue faster (19.00%), while VRTX maintains the higher operating margin (38.13%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for REGN (+36.13%) than for VRTX (+23.32%).
Normalized 1Y performance
VRTX
REGN
Recent returns
VRTX
REGN
Analyst price targets & sentiment
VRTX · 28 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.1/5.0)
Price target range
analyst low$330.00
analyst high$621.00
analyst mean$548.69
current price$451.63
+23.3% upside to analyst mean
REGN · 23 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.7/5.0)
Price target range
analyst low$535.00
analyst high$950.00
analyst mean$833.31
current price$609.94
+36.1% upside to analyst mean
Who should consider this stock?
VRTX may suit investors who:
- →prefer the CF near-monopoly as one of the most durable drug franchises in biotech history
- →value VX-548 non-opioid pain and kidney disease pipeline as large new TAMs that can sustain growth beyond CF saturation
- →want biotech quality with high free cash flow margins and no meaningful debt from Trikafta's pricing power
- →are comfortable with CF market saturation risk and pipeline diversification execution as the primary long-term investment thesis
REGN may suit investors who:
- →prefer Regeneron's multi-blockbuster antibody portfolio with Dupixent still in multi-indication expansion phase
- →value the Veloci-G antibody discovery platform as a continuous pipeline generation engine for novel bispecifics
- →want immunology franchise exposure with Dupixent across atopic dermatitis, asthma, COPD, and multiple new indications
- →are comfortable with EYLEA biosimilar pressure and Dupixent Sanofi collaboration royalty structure
Performance & AI score
| Metric | VRTX | REGN |
|---|---|---|
| AI score | 50.5 | 42.1 |
| AI rank | #443 | #882 |
| Latest close | $451.63 | $609.94 |
| 1M return | +3.99% | -3.23% |
| 6M return | +0.47% | -18.65% |
| 1Y return | +2.18% | +19.86% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | VRTX | REGN |
|---|---|---|
| 1Y ago | $10.07K (+0.7%) started 2025-06-18 | $11.88K (+18.8%) started 2025-06-18 |
| 5Y ago | $24.06K (+140.6%) started 2021-06-21 | $11.46K (+14.6%) started 2021-06-21 |
| 10Y ago | $52.08K (+420.8%) started 2016-06-20 | $17.37K (+73.7%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | VRTX | REGN |
|---|---|---|
| Market cap | $112.92B | $64.18B |
| Trailing P/E | 26.39 | 14.95 |
| Forward P/E | 20.72 | 11.38 |
| Price/Sales | 10.42 | 3.78 |
| EV/Revenue | 8.81 | 3.77 |
| Analyst target | $548.69 | $833.31 |
| Target upside | +23.32% | +36.13% |
Growth, profitability & risk
| Metric | VRTX | REGN |
|---|---|---|
| Revenue growth | 7.80% | 19.00% |
| Earnings growth | 61.40% | -7.20% |
| EPS growth | +61.40% | -7.20% |
| FCF margin | +22.78% | +21.94% |
| Operating margin | 38.13% | 20.66% |
| Profit margin | 35.51% | 29.65% |
| ROIC proxy | 24.20% | 14.55% |
| Return on equity | 24.20% | 14.55% |
| Dividend yield | N/A | 0.61% |
| Beta | 0.31 | 0.24 |
| Debt/equity | 10.26 | 8.61 |
| Current ratio | 3.02 | 3.56 |
| Quick ratio | 2.38 | 2.84 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
VRTX max drawdown23.56%
REGN max drawdown26.05%
VRTX max wkly drop20.71%
REGN max wkly drop12.87%
5Y risk snapshot
VRTX max drawdown29.07%
REGN max drawdown59.69%
VRTX max wkly drop20.71%
REGN max wkly drop20.21%
10Y risk snapshot
VRTX max drawdown41.60%
REGN max drawdown59.69%
VRTX max wkly drop22.29%
REGN max wkly drop20.21%
Performance metrics by period
| Period | Metric | VRTX | REGN |
|---|---|---|---|
| 1Y | Growth | +0.72% | +18.76% |
| CAGR | +0.72% | +18.79% | |
| Sharpe ratio | 0.07 | 0.55 | |
| Max drawdown | 23.56% | 26.05% | |
| Max daily drop | 20.60% | 9.82% | |
| Max wkly drop | 20.71% | 12.87% | |
| 5Y | Growth | +140.61% | +14.48% |
| CAGR | +19.23% | +2.75% | |
| Sharpe ratio | 0.61 | 0.10 | |
| Max drawdown | 29.07% | 59.69% | |
| Max daily drop | 20.60% | 19.01% | |
| Max wkly drop | 20.71% | 20.21% | |
| 10Y | Growth | +420.79% | +73.43% |
| CAGR | +17.95% | +5.66% | |
| Sharpe ratio | 0.53 | 0.19 | |
| Max drawdown | 41.60% | 59.69% | |
| Max daily drop | 20.70% | 19.01% | |
| Max wkly drop | 22.29% | 20.21% |
Business comparison
| Category | VRTX | REGN |
|---|---|---|
| Company | Vertex Pharmaceuticals Incorporated | Regeneron Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Vertex Pharmaceuticals is the global leader in cystic fibrosis (CF) treatment, with Trikafta/Kaftrio generating $8B+ in annual revenue by treating the underlying cause of CF for 90% of CF patients. Vertex is now diversifying into pain (VX-548 non-opioid), kidney disease (IgA nephropathy, FSGS), and gene editing (sickle cell/thalassemia via Casgevy, co-developed with CRISPR Therapeutics). Its CF franchise has very high switching costs and near-100% market share in treatable CF. | Regeneron is a biopharmaceutical company best known for Dupixent (dupilumab, IL-4/IL-13 antibody for atopic dermatitis, asthma, COPD, and other inflammatory diseases), EYLEA (aflibercept for retinal diseases), and Libtayo (cemiplimab, checkpoint inhibitor for skin cancers). Dupixent, developed with Sanofi, is one of the best-selling drugs in the world, generating $13B+ annually. Regeneron's Veloci-G antibody discovery engine enables rapid development of bispecific antibodies and novel biologics. |
| Investor focus | Investors track CF revenue sustainability, VX-548 non-opioid pain launch and label expansion, Casgevy sickle cell/thalassemia patient uptake, IgA nephropathy and kidney disease pipeline, and the overall pipeline diversification timeline beyond CF. | Investors track Dupixent revenue growth and label expansion into new indications, EYLEA HD (high-dose aflibercept) market penetration amid biosimilar competition to original EYLEA, new Veloci-G platform assets in oncology and rare disease, and the Sanofi collaboration economics for Dupixent. |
VRTX strengths
- →Near-monopoly in CF treatment with Trikafta treating 90% of CF patients — one of the most durable drug franchises in biotech
- →VX-548 non-opioid pain drug is a major new market opportunity in a space desperate for non-addictive pain alternatives
- →Casgevy gene editing cure for sickle cell disease and thalassemia represents Vertex's entry into curative gene therapies
REGN strengths
- →Dupixent is a multi-blockbuster in atopic dermatitis, asthma, COPD, and eosinophilic esophagitis with multiple new indications in development
- →Veloci-G platform accelerates antibody drug discovery at scale, enabling rapid generation of bispecific and novel antibody formats
- →EYLEA maintained dominant retinal disease market share for over a decade with EYLEA HD extending the franchise versus biosimilar competition
Risks to watch — VRTX
- →CF market is nearly fully penetrated, limiting organic CF revenue growth and making pipeline diversification critical
- →VX-548 pain drug faces formidable pricing and formulary competition from generic opioids and NSAIDs despite clinical superiority
- →Gene editing therapies (Casgevy) have very high one-time pricing but limited annual patient volumes given disease prevalence
Risks to watch — REGN
- →EYLEA biosimilar competition from Vabysmo (Roche) and generic EYLEA is eroding the retinal franchise
- →Dupixent faces competition from JAK inhibitors (Rinvoq, Olumiant) in atopic dermatitis, though Dupixent's safety profile is superior
- →Revenue concentration in Dupixent and EYLEA creates risk if either franchise underperforms or faces unexpected competition
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →